TCI Bio


TCI Co., Ltd. is a Taiwanese contract development and manufacturing organization specialising in the research, development and production of functional beverages, dietary supplements and skincare products. Headquartered in the Neihu Technology Park in Taipei, TCI evolved from an original trading company founded in 1980 into a CDMO group serving clients across Asia, Europe and North America, and is publicly traded on Taiwan's over-the-counter market under the code 8436.

History

The corporate origins trace back to 1980, when the predecessor trading company was established. In the late 1990s the group created a biomedical division and moved progressively into health-care product development and manufacturing.
In 2011 the company transitioned its business model from an ODM to a CDMO, emphasising integrated bioscience design, proprietary ingredient development and turnkey manufacturing services for clients seeking private-label and brand products.
The firm went public on Taiwan’s OTC market in 2013 with stock code 8436, accelerating capital access for factory expansion, R&D laboratories and overseas business development.
Since the 2010s TCI has expanded into multiple subsidiaries and business lines, pursued international client partnerships, and invested in laboratory and production capacity—reporting a group workforce in the high hundreds and multiple manufacturing sites and laboratories by the early 2020s.

Operations and products

TCI provides end-to-end services for the nutraceutical and cosmetic sectors: market analysis and concept design, ingredient sourcing and proprietary raw material development, formulation R&D, stability and safety testing, pilot production, and full-scale manufacturing for capsules, softgels, liquids, powders, and cosmetic formulations. The company markets private-label products under group consumer channels as well as acting as a CDMO for domestic and international brands.
Subsidiaries and affiliated brands include genetic testing and consumer retail channels, reflecting a diversification strategy across upstream R&D and downstream retail.

Public listing, financials and governance

TCI is listed on Taiwan’s OTC market. Regulatory and investor pages report the company’s registration details, public offering timeline, paid-in capital and disclosure contacts. Quarterly and annual reports are published on the company’s investor relations pages.

Recognition and sustainability

TCI has publicly promoted sustainability initiatives and in recent years participated in corporate sustainability networks. Industry reporting and chamber notices noted TCI’s membership in RE100 initiatives or climate/sustainability collaborations, positioning the company among early adopters in Taiwan’s biotech/manufacturing sector to commit to renewable energy targets and net-zero ambitions.

Contemporary developments and strategy

Throughout the 2020s TCI pursued an acquisition and expansion phase, increasing capacity for CDMO services, establishing additional labs, and extending product portfolios into probiotics, collagen, functional drinks and clinical-grade ingredients. The company emphasizes integrated R&D, regulatory compliance for international markets, and sustainability in manufacturing operations.

Criticism and market challenges

As with many contract manufacturers in the nutraceutical and cosmetic sectors, TCI faces sector-wide pressures including regulatory compliance across multiple jurisdictions, supply-chain volatility, increasing competition from lower-cost regional producers, and the need to demonstrate product efficacy and safety through independent clinical evidence. Publicly available sources emphasize the company’s efforts to address these through expanded testing capabilities and R&D investment; independent media coverage and financial reports remain the primary sources for external assessment of performance and governance.